Vitiligo and the AMG 714

Vitiligo is an autoimmune illness in which T cells, which are part of your body’s immune system, assault melanocytes (the pigment producing cells in the skin). Patches of skin depigmentation result as a result of this (loss of normal skin color). Tissue resident memory T cells (Trm) are thought to be implicated in the attack on melanocytes, according to scientists. The chemical signal IL-15 is required for Trm cells to function. As a result, experts believe that disrupting the IL-15 signal may result in a decrease in Trm cells, which may help with vitiligo. AMG 714 is an investigational medication that inhibits IL-15, which may prevent the immune system from attacking melanocytes and allowing them to create normal skin color (repigmentation).

What information is required of participants?

– Participants will be randomized to one of two groups at random: The research medicine, AMG 714, will be given to one group, while the other will be given an inactive chemical termed a placebo.
– This study is double-blind, which means neither you nor your study doctor will know whether you are getting AMG 714 or a placebo during the study.
– The treatment lasts 12 weeks and includes six clinic visits and two subcutaneous injections every two weeks.
– The follow-up period is generally 36 weeks, with 5 clinic visits during that time.
– Participants may require Narrowband Ultraviolet B light (nbUVB) phototherapy treatment for approximately 24 weeks throughout the follow-up period, which will be supplied at no cost.

– You’ll get the active research medicine 2 out of every 3 times, and the placebo 1 out of every 3 times.

If you meet the following criteria, you may be eligible to participate in the REVEAL study:

– Are you between the ages of 18 and 75 years old?
– A dermatologist has diagnosed you with vitiligo.
– Have a visible amount of vitiligo on your face and body and are willing to discontinue alternative vitiligo treatments